| |
著者: Takayuki Suga, Miho Takenoshita, Takeshi Watanabe, Trang Th Tu, Lou Mikuzuki, Chaoli Hong, Kazuhito Miura, Tatsuya Yoshikawa, Takahiko Nagamine, Akira Toyofuku
雑誌名: Neuropsychiatr Dis Treat. 2019;15:3599-3607. doi: 10.2147/NDT.S235669. Epub 2019 Dec 30.
Abstract/Text
OBJECTIVE: To assess the therapeutic dose and safety of amitriptyline and the outcome following treatment with amitriptyline among older patients with burning mouth syndrome (BMS).
METHODS: 187 consecutive patients were prescribed amitriptyline as a first-line medication from April 2016 to September 2018 and followed-up for >1 month. Patients were divided into 3 groups: group 1, 113 patients aged <65 years; group 2, 52 patients aged between 65 and 74 years; and group 3, 22 patients aged 75 years or older. The visual analog scale (VAS), Pain Catastrophizing Scale (PCS), Somatic Symptom Scale-8 (SSS-8), Patient Global Impression of Change (PGIC), and Short-form McGill Pain Questionnaire (SF-MPQ) were used for analysis.
RESULTS: Thirty-two patients (17 in group 1, 10 in group 2, and 5 in group 3) stopped taking amitriptyline due to side effects. There were no differences among the groups with respect to sex; scores of VAS, PCS, and SSS-8; and drop-out ratio. There were no significant differences in the VAS, PCS, and PGIC scores among the groups after 1 month. The mean daily dose after 1 month was 20.4 ± 8.6 mg in group 1, 17.3 ± 8.7 mg in group 2, and 13.2 ± 5.8 mg in group 3; this difference was significant (p value = 0.003). About 76% of patients showed improvements in their symptoms (PGIC ≥ 3). About 90% of patients reported side effects. No serious side effects occurred.
CONCLUSION: The therapeutic dose of amitriptyline may be lower for older BMS patients than for younger patients.
© 2019 Suga et al.
PMID 31920319 Neuropsychiatr Dis Treat. 2019;15:3599-3607. doi: 10.2147/NDT.S235669. Epub 2019 Dec 30.
|
